Tuesday, 13 September 2022

Zydus receives final approval from the USFDA for Lenalidomide Capsules

Zydus receives final approval from the USFDA for Lenalidomide Capsules
Zydus receives final approval from the USFDA for Lenalidomide Capsules

Zydus Lifesciences Limited’s has received approval from the United States Food and Drug Administration (USFDA) to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The company has received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid®.

Pradip Mahajan Tue, 09/13/2022 - 15:07

source https://www.pharmatutor.org/pharma-news/2022/zydus-receives-final-approval-from-the-usfda-for-lenalidomide-capsules

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...